Neutrophil extracellular traps (NETs) in patients with STEMI. Association with percutaneous coronary intervention and antithrombotic treatments
Neutrophil extracellular traps (NETs) are formed by DNA, histones and proteolytic enzymes, and are produced by activated neutrophils through different mechanisms. In turn, NETs can activate platelets and coagulation cascade favoring thrombotic processes. The aims of this study were to analyze levels...
Gespeichert in:
| Veröffentlicht in: | Thrombosis research 2022-05, Vol.213, p.78-83 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 83 |
|---|---|
| container_issue | |
| container_start_page | 78 |
| container_title | Thrombosis research |
| container_volume | 213 |
| creator | Ferré-Vallverdú, Maria Latorre, Ana María Fuset, María Paz Sánchez, Elena Madrid, Isabel Ten, Francisco Vallés, Juana Santos, María Teresa Bonanad, Santiago Moscardó, Antonio |
| description | Neutrophil extracellular traps (NETs) are formed by DNA, histones and proteolytic enzymes, and are produced by activated neutrophils through different mechanisms. In turn, NETs can activate platelets and coagulation cascade favoring thrombotic processes. The aims of this study were to analyze levels and kinetics of NETs in ST-segment elevation myocardial infarction (STEMI) patients and correlate them with antithrombotic therapy and cardiovascular outcomes at follow-up.
150 consecutive STEMI patients referred to primary percutaneous coronary intervention (pPCI) were included. Citrate anticoagulated blood was extracted immediately before pPCI, 30 min and 24 h after the procedure. As markers of NETS cell free DNA (cfDNA), nucleosomes and citrullinated Histone 3 (citH3) were determined. 46 healthy subjects were included as controls. Patients were follow-up for 1.4 ± 0.56 years.
Before pPCI, NETs markers were elevated in STEMI patients compared to healthy controls (p |
| doi_str_mv | 10.1016/j.thromres.2022.03.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2641512644</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0049384822000718</els_id><sourcerecordid>2641512644</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-f462eb6caff23bbdfb7afa87c2db52519e878e6e812ea60fb9882fa20c27fd0d3</originalsourceid><addsrcrecordid>eNqFUU1v1DAUtBCILoW_UPlYDgn-SBznRlUtUKmUA8vZcpxnrVdJHGynwK_oX65DWq4cbD_ZM288bxC6oKSkhIoPpzIdgx8DxJIRxkrCS0LYC7SjsmkLVjXsJdoRUrUFl5U8Q29iPBFCG9rWr9EZrzkRFac79HAHSwp-ProBw-8UtIFhWAYdcK7niC_v9of4HrsJzzo5mFLEv1w64u-H_debEl_F6I3LL37a7mcIZkl6Ar9EbHzwkw5_Mj1BuM_sFaenPq_k_hrofHIma4FO49r9LXpl9RDh3dN5jn582h-uvxS33z7fXF_dFoYLmQpbCQadMNpaxruut12jrZaNYX1Xs5q2IBsJAiRloAWxXSsls5oRwxrbk56fo8ut7xz8zwViUqOLq_ft64qJitY071WGig1qgo8xgFVzcGO2pShRaxjqpJ7DUGsYinCVw8jEiyeNpRuh_0d7nn4GfNwAkJ3eOwgqmjxjA70LYJLqvfufxiMs5aPj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2641512644</pqid></control><display><type>article</type><title>Neutrophil extracellular traps (NETs) in patients with STEMI. Association with percutaneous coronary intervention and antithrombotic treatments</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Ferré-Vallverdú, Maria ; Latorre, Ana María ; Fuset, María Paz ; Sánchez, Elena ; Madrid, Isabel ; Ten, Francisco ; Vallés, Juana ; Santos, María Teresa ; Bonanad, Santiago ; Moscardó, Antonio</creator><creatorcontrib>Ferré-Vallverdú, Maria ; Latorre, Ana María ; Fuset, María Paz ; Sánchez, Elena ; Madrid, Isabel ; Ten, Francisco ; Vallés, Juana ; Santos, María Teresa ; Bonanad, Santiago ; Moscardó, Antonio</creatorcontrib><description>Neutrophil extracellular traps (NETs) are formed by DNA, histones and proteolytic enzymes, and are produced by activated neutrophils through different mechanisms. In turn, NETs can activate platelets and coagulation cascade favoring thrombotic processes. The aims of this study were to analyze levels and kinetics of NETs in ST-segment elevation myocardial infarction (STEMI) patients and correlate them with antithrombotic therapy and cardiovascular outcomes at follow-up.
150 consecutive STEMI patients referred to primary percutaneous coronary intervention (pPCI) were included. Citrate anticoagulated blood was extracted immediately before pPCI, 30 min and 24 h after the procedure. As markers of NETS cell free DNA (cfDNA), nucleosomes and citrullinated Histone 3 (citH3) were determined. 46 healthy subjects were included as controls. Patients were follow-up for 1.4 ± 0.56 years.
Before pPCI, NETs markers were elevated in STEMI patients compared to healthy controls (p < 0.05); these increased significantly 30 min post pPCI (p ≤ 0.001) and decreased at 24 h but remained elevated compared with the control group (p < 0.05). Patients treated with bivalirudin presented a lower increase of NETs 30 min post pPCI compared to patients treated with heparin (p < 0.05). Cardiovascular risk factors or type of stent implanted did not modify NETs levels. Cit3H (HR = 3.74; 95%CI 1.05–13.4; p = 0.042) and left ventricular ejection fraction ≤35% (HR = 6.84; 95%CI 2–23; p = 0.002) were independent predictors of composite endpoint of myocardial infarction, stroke, stent thrombosis and/or cardiovascular-cause death.
NETs were elevated in STEMI patients, increased by pPCI and decreased thereafter. One of the most specific NETs markers was associated with cardiovascular outcomes.</description><identifier>ISSN: 0049-3848</identifier><identifier>EISSN: 1879-2472</identifier><identifier>DOI: 10.1016/j.thromres.2022.03.002</identifier><identifier>PMID: 35306431</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Citrullinated histone 3 (citH3) ; Extracellular Traps - metabolism ; Fibrinolytic Agents ; Humans ; Myocardial Infarction - metabolism ; Neutrophil extracellular traps (NETs) ; Percutaneous Coronary Intervention ; Primary percutaneous coronary intervention (pPCI) ; ST Elevation Myocardial Infarction - drug therapy ; ST Elevation Myocardial Infarction - surgery ; ST-segment elevation myocardial infarction (STEMI) ; Stroke Volume ; Treatment Outcome ; Ventricular Function, Left</subject><ispartof>Thrombosis research, 2022-05, Vol.213, p.78-83</ispartof><rights>2022 Elsevier Ltd</rights><rights>Copyright © 2022 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-f462eb6caff23bbdfb7afa87c2db52519e878e6e812ea60fb9882fa20c27fd0d3</citedby><cites>FETCH-LOGICAL-c368t-f462eb6caff23bbdfb7afa87c2db52519e878e6e812ea60fb9882fa20c27fd0d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0049384822000718$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35306431$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ferré-Vallverdú, Maria</creatorcontrib><creatorcontrib>Latorre, Ana María</creatorcontrib><creatorcontrib>Fuset, María Paz</creatorcontrib><creatorcontrib>Sánchez, Elena</creatorcontrib><creatorcontrib>Madrid, Isabel</creatorcontrib><creatorcontrib>Ten, Francisco</creatorcontrib><creatorcontrib>Vallés, Juana</creatorcontrib><creatorcontrib>Santos, María Teresa</creatorcontrib><creatorcontrib>Bonanad, Santiago</creatorcontrib><creatorcontrib>Moscardó, Antonio</creatorcontrib><title>Neutrophil extracellular traps (NETs) in patients with STEMI. Association with percutaneous coronary intervention and antithrombotic treatments</title><title>Thrombosis research</title><addtitle>Thromb Res</addtitle><description>Neutrophil extracellular traps (NETs) are formed by DNA, histones and proteolytic enzymes, and are produced by activated neutrophils through different mechanisms. In turn, NETs can activate platelets and coagulation cascade favoring thrombotic processes. The aims of this study were to analyze levels and kinetics of NETs in ST-segment elevation myocardial infarction (STEMI) patients and correlate them with antithrombotic therapy and cardiovascular outcomes at follow-up.
150 consecutive STEMI patients referred to primary percutaneous coronary intervention (pPCI) were included. Citrate anticoagulated blood was extracted immediately before pPCI, 30 min and 24 h after the procedure. As markers of NETS cell free DNA (cfDNA), nucleosomes and citrullinated Histone 3 (citH3) were determined. 46 healthy subjects were included as controls. Patients were follow-up for 1.4 ± 0.56 years.
Before pPCI, NETs markers were elevated in STEMI patients compared to healthy controls (p < 0.05); these increased significantly 30 min post pPCI (p ≤ 0.001) and decreased at 24 h but remained elevated compared with the control group (p < 0.05). Patients treated with bivalirudin presented a lower increase of NETs 30 min post pPCI compared to patients treated with heparin (p < 0.05). Cardiovascular risk factors or type of stent implanted did not modify NETs levels. Cit3H (HR = 3.74; 95%CI 1.05–13.4; p = 0.042) and left ventricular ejection fraction ≤35% (HR = 6.84; 95%CI 2–23; p = 0.002) were independent predictors of composite endpoint of myocardial infarction, stroke, stent thrombosis and/or cardiovascular-cause death.
NETs were elevated in STEMI patients, increased by pPCI and decreased thereafter. One of the most specific NETs markers was associated with cardiovascular outcomes.</description><subject>Citrullinated histone 3 (citH3)</subject><subject>Extracellular Traps - metabolism</subject><subject>Fibrinolytic Agents</subject><subject>Humans</subject><subject>Myocardial Infarction - metabolism</subject><subject>Neutrophil extracellular traps (NETs)</subject><subject>Percutaneous Coronary Intervention</subject><subject>Primary percutaneous coronary intervention (pPCI)</subject><subject>ST Elevation Myocardial Infarction - drug therapy</subject><subject>ST Elevation Myocardial Infarction - surgery</subject><subject>ST-segment elevation myocardial infarction (STEMI)</subject><subject>Stroke Volume</subject><subject>Treatment Outcome</subject><subject>Ventricular Function, Left</subject><issn>0049-3848</issn><issn>1879-2472</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUU1v1DAUtBCILoW_UPlYDgn-SBznRlUtUKmUA8vZcpxnrVdJHGynwK_oX65DWq4cbD_ZM288bxC6oKSkhIoPpzIdgx8DxJIRxkrCS0LYC7SjsmkLVjXsJdoRUrUFl5U8Q29iPBFCG9rWr9EZrzkRFac79HAHSwp-ProBw-8UtIFhWAYdcK7niC_v9of4HrsJzzo5mFLEv1w64u-H_debEl_F6I3LL37a7mcIZkl6Ar9EbHzwkw5_Mj1BuM_sFaenPq_k_hrofHIma4FO49r9LXpl9RDh3dN5jn582h-uvxS33z7fXF_dFoYLmQpbCQadMNpaxruut12jrZaNYX1Xs5q2IBsJAiRloAWxXSsls5oRwxrbk56fo8ut7xz8zwViUqOLq_ft64qJitY071WGig1qgo8xgFVzcGO2pShRaxjqpJ7DUGsYinCVw8jEiyeNpRuh_0d7nn4GfNwAkJ3eOwgqmjxjA70LYJLqvfufxiMs5aPj</recordid><startdate>202205</startdate><enddate>202205</enddate><creator>Ferré-Vallverdú, Maria</creator><creator>Latorre, Ana María</creator><creator>Fuset, María Paz</creator><creator>Sánchez, Elena</creator><creator>Madrid, Isabel</creator><creator>Ten, Francisco</creator><creator>Vallés, Juana</creator><creator>Santos, María Teresa</creator><creator>Bonanad, Santiago</creator><creator>Moscardó, Antonio</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202205</creationdate><title>Neutrophil extracellular traps (NETs) in patients with STEMI. Association with percutaneous coronary intervention and antithrombotic treatments</title><author>Ferré-Vallverdú, Maria ; Latorre, Ana María ; Fuset, María Paz ; Sánchez, Elena ; Madrid, Isabel ; Ten, Francisco ; Vallés, Juana ; Santos, María Teresa ; Bonanad, Santiago ; Moscardó, Antonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-f462eb6caff23bbdfb7afa87c2db52519e878e6e812ea60fb9882fa20c27fd0d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Citrullinated histone 3 (citH3)</topic><topic>Extracellular Traps - metabolism</topic><topic>Fibrinolytic Agents</topic><topic>Humans</topic><topic>Myocardial Infarction - metabolism</topic><topic>Neutrophil extracellular traps (NETs)</topic><topic>Percutaneous Coronary Intervention</topic><topic>Primary percutaneous coronary intervention (pPCI)</topic><topic>ST Elevation Myocardial Infarction - drug therapy</topic><topic>ST Elevation Myocardial Infarction - surgery</topic><topic>ST-segment elevation myocardial infarction (STEMI)</topic><topic>Stroke Volume</topic><topic>Treatment Outcome</topic><topic>Ventricular Function, Left</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ferré-Vallverdú, Maria</creatorcontrib><creatorcontrib>Latorre, Ana María</creatorcontrib><creatorcontrib>Fuset, María Paz</creatorcontrib><creatorcontrib>Sánchez, Elena</creatorcontrib><creatorcontrib>Madrid, Isabel</creatorcontrib><creatorcontrib>Ten, Francisco</creatorcontrib><creatorcontrib>Vallés, Juana</creatorcontrib><creatorcontrib>Santos, María Teresa</creatorcontrib><creatorcontrib>Bonanad, Santiago</creatorcontrib><creatorcontrib>Moscardó, Antonio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Thrombosis research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ferré-Vallverdú, Maria</au><au>Latorre, Ana María</au><au>Fuset, María Paz</au><au>Sánchez, Elena</au><au>Madrid, Isabel</au><au>Ten, Francisco</au><au>Vallés, Juana</au><au>Santos, María Teresa</au><au>Bonanad, Santiago</au><au>Moscardó, Antonio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neutrophil extracellular traps (NETs) in patients with STEMI. Association with percutaneous coronary intervention and antithrombotic treatments</atitle><jtitle>Thrombosis research</jtitle><addtitle>Thromb Res</addtitle><date>2022-05</date><risdate>2022</risdate><volume>213</volume><spage>78</spage><epage>83</epage><pages>78-83</pages><issn>0049-3848</issn><eissn>1879-2472</eissn><abstract>Neutrophil extracellular traps (NETs) are formed by DNA, histones and proteolytic enzymes, and are produced by activated neutrophils through different mechanisms. In turn, NETs can activate platelets and coagulation cascade favoring thrombotic processes. The aims of this study were to analyze levels and kinetics of NETs in ST-segment elevation myocardial infarction (STEMI) patients and correlate them with antithrombotic therapy and cardiovascular outcomes at follow-up.
150 consecutive STEMI patients referred to primary percutaneous coronary intervention (pPCI) were included. Citrate anticoagulated blood was extracted immediately before pPCI, 30 min and 24 h after the procedure. As markers of NETS cell free DNA (cfDNA), nucleosomes and citrullinated Histone 3 (citH3) were determined. 46 healthy subjects were included as controls. Patients were follow-up for 1.4 ± 0.56 years.
Before pPCI, NETs markers were elevated in STEMI patients compared to healthy controls (p < 0.05); these increased significantly 30 min post pPCI (p ≤ 0.001) and decreased at 24 h but remained elevated compared with the control group (p < 0.05). Patients treated with bivalirudin presented a lower increase of NETs 30 min post pPCI compared to patients treated with heparin (p < 0.05). Cardiovascular risk factors or type of stent implanted did not modify NETs levels. Cit3H (HR = 3.74; 95%CI 1.05–13.4; p = 0.042) and left ventricular ejection fraction ≤35% (HR = 6.84; 95%CI 2–23; p = 0.002) were independent predictors of composite endpoint of myocardial infarction, stroke, stent thrombosis and/or cardiovascular-cause death.
NETs were elevated in STEMI patients, increased by pPCI and decreased thereafter. One of the most specific NETs markers was associated with cardiovascular outcomes.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>35306431</pmid><doi>10.1016/j.thromres.2022.03.002</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0049-3848 |
| ispartof | Thrombosis research, 2022-05, Vol.213, p.78-83 |
| issn | 0049-3848 1879-2472 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2641512644 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Citrullinated histone 3 (citH3) Extracellular Traps - metabolism Fibrinolytic Agents Humans Myocardial Infarction - metabolism Neutrophil extracellular traps (NETs) Percutaneous Coronary Intervention Primary percutaneous coronary intervention (pPCI) ST Elevation Myocardial Infarction - drug therapy ST Elevation Myocardial Infarction - surgery ST-segment elevation myocardial infarction (STEMI) Stroke Volume Treatment Outcome Ventricular Function, Left |
| title | Neutrophil extracellular traps (NETs) in patients with STEMI. Association with percutaneous coronary intervention and antithrombotic treatments |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T14%3A28%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neutrophil%20extracellular%20traps%20(NETs)%20in%20patients%20with%20STEMI.%20Association%20with%20percutaneous%20coronary%20intervention%20and%20antithrombotic%20treatments&rft.jtitle=Thrombosis%20research&rft.au=Ferr%C3%A9-Vallverd%C3%BA,%20Maria&rft.date=2022-05&rft.volume=213&rft.spage=78&rft.epage=83&rft.pages=78-83&rft.issn=0049-3848&rft.eissn=1879-2472&rft_id=info:doi/10.1016/j.thromres.2022.03.002&rft_dat=%3Cproquest_cross%3E2641512644%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2641512644&rft_id=info:pmid/35306431&rft_els_id=S0049384822000718&rfr_iscdi=true |